September 14 | 2020
2cureX launches world’s first CE-marked microtumor test service
Read more
August 27 | 2020
2cureX AB (“2cureX”) hereby publishes the interim report for the first half of 2020.
Read more
August 4 | 2020
First day for trading in TO1 series warrants
Read more
July 13 | 2020
Record date for allotment of warrants of series TO1 is set to July 17, 2020
Read more
July 6 | 2020
2cureX completes a heavily oversubscribed directed issue of approximately SEK 40 million
Read more
July 6 | 2020
2cureX AB intends to carry out a directed issue of units
Read more
July 3 | 2020
2cureX AB expands its Board of Directors with Michael Lutz and Nils Brünner
Read more
July 2 | 2020
Bulletin from the Extraordinary General Meeting in 2cureX AB (publ)
Read more
July 1 | 2020
2cureX Newsletter July’20
Read more
June 25 | 2020
2cureX receives third payment from the EU’ Horizon 2020 SME- Instrument Program
Read more
June 17 | 2020
Notice to attend the extraordinary general meeting of 2cureX AB (publ)
Read more
June 16 | 2020
2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients
Read more
June 9 | 2020
Change of Certified Adviser to Redeye AB
Read more
May 29 | 2020
2cureX moves forward with the commercialization of IndiTreat by signing a new distributor agreement in Portugal
Read more
May 28 | 2020
Communique from the Annual General Meeting in 2cureX AB (publ)
Read more
May 28 | 2020
2cureX publishes interim report for the first quarter of 2020
Read more
May 7 | 2020
2cureX publishes the annual report for the fiscal year 2019
Read more